Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Merck is attracting bullish attention due to its low valuation and strong dividend, but dark clouds hover over its future.

Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of ...

New insights into why patients with cancer choose to go with recommendations from a second opinion rather than the initial ...